EWP
ALXN

Engrave Wealth Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Engrave Wealth Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-92
Closed -$10K – 466
2020
Q2 		$10K Buy
92
+41
+80% +$4.35K 0.01% 251
2020
Q1 		$4K Sell
51
-64
-56% -$6.28K ﹤0.01% 305
2019
Q4 		$12K Buy
+115
New +$12.3K 0.01% 286

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Engrave Wealth Partners's ALXN Position: Q3 2020 in Review

Engrave Wealth Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 92 shares — an estimated $10K sold.

Engrave Wealth Partners first reported a position in ALXN in Q4 2019 and held it in 3 quarters. The position peaked at $12K in Q4 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Engrave Wealth Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Engrave Wealth Partners sold 92 Alexion Pharmaceuticals shares in Q3 2020, an estimated $10K.
  • Engrave Wealth Partners first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Engrave Wealth Partners's Alexion Pharmaceuticals position peaked at $12K in Q4 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Engrave Wealth Partners's 13F filing for Q3 2020, filed 8 Oct 2020.